Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCP102 is a synthetic peptide candidate developed by NovaCell Technology for cosmetic and aesthetic applications. It is designed to target the laminin receptor, a cell surface protein that plays a critical role in cell-matrix interactions, adhesion, and signaling within the dermis. By modulating the activity of the laminin receptor, NCP102 aims to improve skin properties, specifically targeting wrinkle reduction and skin whitening (lightening). Furthermore, the peptide is being investigated for its potential application as a dermal filler to restore skin volume and improve texture. It is part of NovaCell's pipeline of functional peptides discovered through their proprietary Peptoid/Peptide library platform.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NCP102.